Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad168 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Chen Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi' an, China. Hauptthemen laut MEDLINE: Psoriasis, Scalp Dermatoses. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Shanghai Ruizhi Medical Technology Co Ltd.
Abstract (Originalsprache)
Background
Controlling the relapses of scalp psoriasis is a clinical issue.
Objectives
To evaluate the efficacy and safety of a supramolecular active zinc antidandruff hair conditioner in managing scalp psoriasis (SP).
Methods
This multicentre randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial enrolled 211 patients with SP between October 2018 and June 2019. The participants were randomized 1 : 1 : 1 to the experimental (supramolecular active zinc antidandruff hair conditioner), placebo (supramolecular hydrogel) or positive control (calcipotriol ointment) group. The primary efficacy endpoint was the disease control rate at the end of the fourth week of treatment, measured using the Investigator’s Global Assessment score.
Results
This study included 70, 70 and 71 participants in the experiment, control and placebo groups, respectively. The disease control rates of SP at the end of week 4 of treatment in the full-analysis set (FAS) were 39%, 25% and 37% in the experimental, placebo and control groups. The margin of superiority between the experimental and placebo groups was > 0 [96% confidence interval (CI) 13.22% (0.43% to ∞)] in the FAS. The experimental group was superior to the placebo group. The noninferiority margin between the experiment and control groups was > –15% [96% CI –1.43% (–14.91% to ∞)] in the FAS. The experimental group was not inferior to the control group.
Conclusions
Supramolecular active zinc antidandruff hair conditioner was helpful for the treatment of SP, and it has good clinical efficacy in maintaining therapeutic effect and assisting in preventing the recurrence of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi' an, China.
- Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, China.
- Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
- Department of Dermatology, Strategic Support Force Specialty Medical Center (306 Hospital of PLA), Beijing, China.
Förderung
- Shanghai Ruizhi Medical Technology Co Ltd
Zitieren
APA
Yu, C., Yu, N., Jiang, X., Gao, X., Lv, S., & Wang, G. (2023). Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad168
Vancouver
Yu C, Yu N, Jiang X, Gao X, Lv S, Wang G. Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad168
BibTeX
@article{Yu2023,
author = {Yu, Chen and Yu, Nan and Jiang, Xian and Gao, Xinghua and Lv, Shichao and Wang, Gang},
title = {Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad168}
}
EUVIMED